Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Debt Repayments (2020)

Anika Therapeutics (ANIK) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $25.0 million as the latest value for Q4 2020.

  • Quarterly Long-Term Debt Repayments changed N/A to $25.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Dec 2021, changed 0.0% year-over-year, with the annual reading at $50.3 million for FY2020, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2020 was $25.0 million at Anika Therapeutics, roughly flat from $25.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $25.0 million in Q3 2020, with the low at $25.0 million in Q4 2020.